DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
IDXX logo

IDEXX Laboratories, Inc. Stock Price

NasdaqGS:IDXX Community·US$40.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 74 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

IDXX Share Price Performance

US$515.30
-128.80 (-20.00%)
​
US$709.14
Fair Value
US$515.30
-128.80 (-20.00%)
27.3% undervalued intrinsic discount
US$709.14
Fair Value
Price US$515.30
AnalystConsensusTarget US$709.14
AnalystHighTarget US$805.00
AnalystLowTarget US$533.63
Wed, 1 Jul 26
Fair ValueUS$709.14
Share Pricen/a

IDXX Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$709.14 27.3% undervalued intrinsic discount

IDXX: Expanding Installed Base Will Drive Accelerating Business Momentum Ahead

1users have liked this narrative
0users have commented on this narrative
25users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$805 36.0% undervalued intrinsic discount

Global Pet Ownership And AI Diagnostics Will Expand Market Opportunities

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$533.63 3.4% undervalued intrinsic discount

Declining Pet Ownership And Rising Compliance Costs Will Erode Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
IDXX logo
IDEXX Laboratories
3.4% undervalued intrinsic discount
Updated

Declining Pet Ownership And Rising Compliance Costs Will Erode Margins

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 21 Sep
Read Narrative
IDXX logo
IDEXX Laboratories
36.0% undervalued intrinsic discount

Global Pet Ownership And AI Diagnostics Will Expand Market Opportunities

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 3 Jun
Read Narrative
IDXX logo
IDEXX Laboratories
27.3% undervalued intrinsic discount

IDXX: Expanding Installed Base Will Drive Accelerating Business Momentum Ahead

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 1 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
IDXX logo

IDXX: Demand Doubts Have Narrowed, Sustaining Test Intensity Is The Real Risk

Fair Value: US$533.63 3.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
IDXX logo

IDXX: Expanded Diagnostics And Reset Expectations Will Support Future Shareholder Value

Fair Value: US$709.14 27.3% undervalued intrinsic discount
25 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
IDXX logo

IDXX: Recurring Diagnostics And AI Cancer Testing Will Support Future Earnings Power

Fair Value: US$805 36.0% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Solid track record with excellent balance sheet.

1 Risk
4 Rewards
View Full Analysis

IDEXX Laboratories, Inc. Key Details

US$4.6b

Revenue

US$1.7b

Cost of Revenue

US$2.8b

Gross Profit

US$1.7b

Other Expenses

US$1.1b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
14.47
62.45%
25.03%
60.1%
View Full Analysis

About IDXX

Founded
1983
Employees
11000
CEO
Michael Erickson
WebsiteView website
www.idexx.com

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Recent IDXX News & Updates

Recent updates

No updates

IDEXX Laboratories, Inc. Competitors

ABT logo

Abbott Laboratories

Symbol: NYSE:ABT
Market cap: US$177.6b
ISRG logo

Intuitive Surgical

Symbol: NasdaqGS:ISRG
Market cap: US$141.9b
MDT logo

Medtronic

Symbol: NYSE:MDT
Market cap: US$117.8b
CVS logo

CVS Health

Symbol: NYSE:CVS
Market cap: US$113.6b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide